Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function
PCSK9 inhibition reduces LpPLA<sub>2</sub> and IP-10 without changing global inflammatory response or antioxidant function of HDL, which might indicate a decrease in chronic vascular inflammation without an undesired broad systemic immune alteration.
Authors
- Adrian Doevelaar (ORCID: https://orcid.org/0000-0002-6160-8402)
- Jonas Kolodziej
- Johannes Korth (ORCID: https://orcid.org/0000-0003-4898-0389)
- M Seidel
- Nina Babel
- Westhoff TH
- Benjamin Rohn
- Felix S. Seibert
- Sebastian Bertram
- Nikolaos Pagonas
Institutions
- Universitätsklinik Marien Hospital Herne (DE)
- PHV Dialysezentrum (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jacl.2026.02.003
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00